68 related articles for article (PubMed ID: 38473407)
1. Discovery and biological evaluation of biaryl acetamide derivatives as selective and in vivo active sphingosine kinase-2 inhibitors.
Li Y; Li G; Wang Y; Li L; Song Y; Cao F; Yang K
Eur J Med Chem; 2024 Jun; 275():116577. PubMed ID: 38875809
[TBL] [Abstract][Full Text] [Related]
2. Recent Progress in the Development of Opaganib for the Treatment of Covid-19.
Smith CD; Maines LW; Keller SN; Katz Ben-Yair V; Fathi R; Plasse TF; Levitt ML
Drug Des Devel Ther; 2022; 16():2199-2211. PubMed ID: 35855741
[TBL] [Abstract][Full Text] [Related]
3. Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.
Asumda FZ; Campbell NA; Hassan MA; Fathi R; Vasquez Rico DF; Kiem M; Vang EV; Kim YH; Luo X; O'Brien DR; Buhrow SA; Reid JM; Moore MJ; Ben-Yair VK; Levitt ML; Leiting JL; Abdelrahman AM; Zhu X; Lucien F; Truty MJ; Roberts LR
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473407
[TBL] [Abstract][Full Text] [Related]
4. Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy.
Maines LW; Schrecengost RS; Zhuang Y; Keller SN; Smith RA; Green CL; Smith CD
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361977
[TBL] [Abstract][Full Text] [Related]
5. Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
Maines LW; Keller SN; Smith CD
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069222
[TBL] [Abstract][Full Text] [Related]
6. Activation of the anti-cancer agent upamostat by the mARC enzyme system.
Froriep D; Clement B; Bittner F; Mendel RR; Reichmann D; Schmalix W; Havemeyer A
Xenobiotica; 2013 Sep; 43(9):780-4. PubMed ID: 23379481
[TBL] [Abstract][Full Text] [Related]
7. Upamostat: a serine protease inhibitor for antiviral, gastrointestinal, and anticancer indications.
Plasse TF; Fathi R; Fehrmann C; McComsey GA
Expert Opin Investig Drugs; 2023; 32(12):1095-1103. PubMed ID: 37970658
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
Kang Y; Sundaramoorthy P; Gasparetto C; Feinberg D; Fan S; Long G; Sellars E; Garrett A; Tuchman SA; Reeves BN; Li Z; Liu B; Ogretmen B; Maines L; Ben-Yair VK; Smith C; Plasse T
Ann Hematol; 2023 Feb; 102(2):369-383. PubMed ID: 36460794
[TBL] [Abstract][Full Text] [Related]
9. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma.
Czauderna C; Kirstein MM; Tews HC; Vogel A; Marquardt JU
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34202401
[TBL] [Abstract][Full Text] [Related]
10. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
11. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.
Wang M; Chen Z; Guo P; Wang Y; Chen G
J Cell Mol Med; 2021 Jan; 25(2):618-628. PubMed ID: 33277810
[TBL] [Abstract][Full Text] [Related]
12. Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine.
Leiting JL; Murphy SJ; Bergquist JR; Hernandez MC; Ivanics T; Abdelrahman AM; Yang L; Lynch I; Smadbeck JB; Cleary SP; Nagorney DM; Torbenson MS; Graham RP; Roberts LR; Gores GJ; Smoot RL; Truty MJ
JHEP Rep; 2020 Apr; 2(2):100068. PubMed ID: 32181445
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo.
Song K; Dai L; Long X; Cui X; Liu Y; Di W
Onco Targets Ther; 2019; 12():4437-4449. PubMed ID: 31239712
[No Abstract] [Full Text] [Related]
14. Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.
Ding X; Zhang Y; Huang T; Xu G; Peng C; Chen G; Kong B; Friess H; Shen S; Lv Y; Roberts LR; Wang L; Zou X
Am J Cancer Res; 2019; 9(3):546-561. PubMed ID: 30949409
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
